Authors’ reply

We would like to thank Kountouras et al for their comment on our review recently published in Annals of Gastroenterology [1]. Kountouras et al emphasized the potential effect of trimebutine in modulating symptoms related to both irritable bowel syndrome (IBS) and gastroesophageal reflux disease (GERD), especially when these symptoms overlap in the same patient